News

UroGen outlines $5B market opportunity as UGN-102 FDA review nears and commercial launch preparations accelerate
Q1 2025 Management View Liz Barrett, President and Chief Executive Officer, highlighted that "the new drug application for ...
Trump signs executive order setting 30-day deadline for drugmakers to lower prescription drug costs
Trump's executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the U.S. or face new limits ...
JD Supra3h
FDA Identifies Data Quality and Study Conduct Concerns With Raptim Research and Requires Sponsors to Submit Replacement Study Data
The Food and Drug Administration (FDA) recently announced that it had identified “significant data integrity and study conduct concerns” ...
Q&A: AI speeds up search for RNA-targeting drugs, opening new therapeutic possibilities
The majority of RNAs in each of our cells don't code for any of the thousands of proteins that make up our bodies. Instead, ...
Generative AI is on track to shape the future of drug design
Using advanced artificial intelligence, researchers have developed a novel method to make drug development faster and more ...
Euractiv7h
Ireland’s health authority denies its to blame for cancer drug delays
Ireland’s Health and Safety Executive has criticised a new report revealing the country’s shocking last place in Western Europe for new oncology drug access.
The Manila Times7h
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...
Roche to invest $700 million in new drug manufacturing facility in North Carolina
Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in Holly ...